Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in CNS Kohlmeier-Degos Disease
NCT05998395Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in malignant atrophic papulosis (MAP), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib at 72 weeks. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
malignant atrophic papulosis (MAP)
Beyond the preview
Go deeper on NCT05998395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998395.